Abstract
Objectives To assess the association of specific comorbid conditions to COVID-19 deaths in Florida among decedents 16 to 64 years of age.
Methods This report uses Florida vital statistics death data over the period of March 1, 2020 through January 16, 2021, to estimate the effects of comorbid conditions on COVID-19 mortality for decedents 16 to 64 years of age. All cases of COVID-19 death occurring in Florida, regardless of resident status, were evaluated. The comorbidities, or contributing causes of death, identified in this report include Down syndrome, asthma, diabetes, pulmonary fibrosis, obesity, dementia, immunodeficiency, kidney disease, chronic obstructive pulmonary disease, hypertension, heart disease, and chronic liver disease and cirrhosis. The study uses a binary logistic regression to examine the relationship between COVID-19 and non-COVID-19 death and contributing causes of death based on information in the death record. Odds ratios were calculated as a residual of the logistic regression.
Results Among COVID-19 deaths, Down syndrome was 15.26 times more likely to be a contributing cause of death compared to non-COVID-19 deaths followed by asthma (OR 7.74), diabetes (OR 6.11), pulmonary fibrosis (OR 5.13), obesity (OR 4.66), dementia (OR 4.51), immunodeficiency (OR 2.49), and kidney disease (OR 2.13). Chronic liver disease and cirrhosis (OR 0.95) and cancer (OR 0.79) had lower odds of being a contributing cause of death.
Conclusions Heart disease, chronic liver disease and cirrhosis, and cancer were not risk factors for death from COVID-19 among decedents. Additional studies are needed to elucidate associations between race/ethnicity, socioeconomic status, and behavioral factors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There is no author conflict of interest or third party funding related to this article.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Exempt review. Florida Department of Health
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest: None
Data Availability
The datasets generated during and/or analyzed during the current study are not publicly available due to HIPPA and PHI privacy but may be available from the Florida Department of Health, Division of Public Health Statistics and Performance Management through appropriate data use agreements on reasonable request.
